304 related articles for article (PubMed ID: 31782805)
1. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in leukaemia.
Mu X; Chen C; Dong L; Kang Z; Sun Z; Chen X; Zheng J; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2023 Jun; 55(6):974-987. PubMed ID: 37272727
[TBL] [Abstract][Full Text] [Related]
3. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia.
Agrawal V; Gbolahan OB; Stahl M; Zeidan AM; Zaid MA; Farag SS; Konig H
Curr Cancer Drug Targets; 2020; 20(7):473-489. PubMed ID: 32357813
[TBL] [Abstract][Full Text] [Related]
4. Novel Approaches to Acute Myeloid Leukemia Immunotherapy.
Beyar-Katz O; Gill S
Clin Cancer Res; 2018 Nov; 24(22):5502-5515. PubMed ID: 29903894
[TBL] [Abstract][Full Text] [Related]
5. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy prospects for acute myeloid leukaemia.
Barrett AJ; Le Blanc K
Clin Exp Immunol; 2010 Aug; 161(2):223-32. PubMed ID: 20529084
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the immune system in acute myeloid leukaemia.
Austin R; Smyth MJ; Lane SW
Crit Rev Oncol Hematol; 2016 Jul; 103():62-77. PubMed ID: 27247119
[TBL] [Abstract][Full Text] [Related]
9. Catch me if you can: how AML and its niche escape immunotherapy.
Tettamanti S; Pievani A; Biondi A; Dotti G; Serafini M
Leukemia; 2022 Jan; 36(1):13-22. PubMed ID: 34302116
[TBL] [Abstract][Full Text] [Related]
10. How to address second and therapy-related acute myelogenous leukaemia.
Oliai C; Schiller G
Br J Haematol; 2020 Jan; 188(1):116-128. PubMed ID: 31863469
[TBL] [Abstract][Full Text] [Related]
11. Developmental approaches in immunological control of acute myelogenous leukaemia.
Torelli GF; Orsini E; Guarini A; Kell J; Foà R
Best Pract Res Clin Haematol; 2001 Mar; 14(1):189-209. PubMed ID: 11355931
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
Smits EL; Lee C; Hardwick N; Brooks S; Van Tendeloo VF; Orchard K; Guinn BA
Cancer Immunol Immunother; 2011 Jun; 60(6):757-69. PubMed ID: 21519825
[TBL] [Abstract][Full Text] [Related]
13. Advances in immunotherapy for pediatric acute myeloid leukemia.
Bonifant CL; Velasquez MP; Gottschalk S
Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.
Gbolahan OB; Zeidan AM; Stahl M; Abu Zaid M; Farag S; Paczesny S; Konig H
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758974
[TBL] [Abstract][Full Text] [Related]
16. A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition.
Koshy AG; Daver NG; Fathi AT
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101220. PubMed ID: 33279176
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
Cheuk AT; Guinn BA
Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
[TBL] [Abstract][Full Text] [Related]
18. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.
Loke J; Malladi R; Moss P; Craddock C
Br J Haematol; 2020 Jan; 188(1):129-146. PubMed ID: 31823351
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
Nahas MR; Stroopinsky D; Rosenblatt J; Cole L; Pyzer AR; Anastasiadou E; Sergeeva A; Ephraim A; Washington A; Orr S; McMasters M; Weinstock M; Jain S; Leaf RK; Ghiasuddin H; Rahimian M; Liegel J; Molldrem JJ; Slack F; Kufe D; Avigan D
Br J Haematol; 2019 May; 185(4):679-690. PubMed ID: 30828801
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic strategies for relapse control in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Hellstrand K
Blood Rev; 2013 Sep; 27(5):209-16. PubMed ID: 23871358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]